Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05679401 · ClinicalTrials.gov registry record · Phase 3
A Study With Imlifidase in Anti-GBM Disease
A Phase 3 study, sponsored by Hansa Biopharma AB.
- Terminated
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT05679401 is a Phase 3 study that was terminated before completion, run by Hansa Biopharma AB. The registered enrollment target is 50 participants.
The verdict
NCT05679401, a Phase 3 study, was terminated before completion, sponsored by Hansa Biopharma AB.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.
Interventions
- DRUG Glucocorticoids
- DRUG Imlifidase
- PROCEDURE Plasma exchange (PLEX)
- DRUG Cyclophosphamide (CYC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2026-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05679401
The ClinicalTrials.gov registry entry for NCT05679401 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hansa Biopharma AB, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Glucocorticoids is the first listed.
NCT05679401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05679401 about?
NCT05679401 is a clinical study titled "A Study With Imlifidase in Anti-GBM Disease". An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.
What is the current status of trial NCT05679401?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2022-12-22. Estimated completion is 2026-02-02.
What interventions are being tested in trial NCT05679401?
The interventions under investigation include: Glucocorticoids (DRUG), Imlifidase (DRUG), Plasma exchange (PLEX) (PROCEDURE), Cyclophosphamide (CYC) (DRUG).
Who is sponsoring clinical trial NCT05679401?
This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.